Icon study trials

Government and Public Health Solutions. Traumatic Brain Injury: From identifying biomarkers to improving clinical trial efficiency This whitepaper looks at the impact of TBI on different populations as well as challenges and opportunities in clinical research. Looking for a career in global public health? See our available roles. Learn more in our factsheet. It can be used to fit models to many different types of data.

PDx-Pop software seamlessly integrates with existing tools and its own automated methods to expedite the iterative process of population pharmacokinetic modeling and analysis.

We can serve your early phase testing needs with breakthrough methodologies and proven expertise in high-precision ECG data collection. Our multi-disciplinary experts have the experience to address the most demanding drug development challenges to:.

Home Services Early Phase. Diversity initiatives are a hallmark of clinical research. Workplace diversity encourages collaboration and innovation — every team member brings their own unique backgrounds, experiences, and perspectives at ICON. COVID disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus.

Learn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients.

Regulatory considerations for biotech The importance of regulatory strategy Read the whitepaper. Spotlight on regulatory reforms in China A guide to the evolving regulatory environment and country-specific requirements Read the whitepaper. Diversity and inclusion in clinical trials Paving the way for diversity and inclusion in clinical trials: establishing a platform for improvement Read the whitepaper.